The sensitivity to cisplatin can be predicted by examining the expression of SLFN11 via immunohistochemical analysis prior to CRT; this prediction can facilitate the selection of more effective treatments for patients with HNSCC. This evidence concerns the gene SLFN11 and head and neck squamous cell carcinoma.